Humacyte, Inc.
HUMAHumacyte, Inc. in brief
Humacyte, Inc. is a listed company in the Biotechnology industry, based in Durham, North Carolina, USA. Its market value was $125 M on 28 October 2026, which makes it the 17,923rd largest listed company in the world and the 3,402nd largest in the USA on this site. In the year to December 2025 it had sales of $2 M and a net loss of $41 M. Laura E. Niklason is its chief executive. Its largest product and service lines by sales in 2025 were Contract Revenue (32%). Its shares trade under the symbol HUMA (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Humacyte, Inc.
Humacyte is a Clinical Stage Biotechnology Platform company developing universally implantable bioengineered human tissue at a commercial scale with the goal of improving the lives of patients and transforming the practice of medicine. The company total assets are 101 million USD as on 2020. The headquarters is in USA.
Humacyte, Inc. timeline
- 2020
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering as Alpha Healthcare Acquisition Corp.Final prospectus filed with the SEC on 18 September 2020; shares registered for exchange trading on 17 September 2020. The blank-check company later merged with the business that carries the name today.
- 2021
- ✎Renamed Humacyte, Inc.Formerly Alpha Healthcare Acquisition Corp..
Events of Humacyte, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,984 (Jan 2022) · #3,500 (Dec 2022) · #3,175 (Jul 2023) · #2,998 (Jan 2024) · #1,638 (Mar 2026) · #3,186 (Aug 2026) · #3,456 (Oct 2026) · #3,406 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 51.9×
- Price / book
- 40.2×
- Free cash flow yield
- -84.7%
- Net margin (TTM)
- -3932.0%
- Operating margin
- -5301.0%
- Return on equity
- -3046.9%
- Liabilities / assets
- 97.3%
- Net debt
- $-15M
- R&D / revenue
- 3397.1%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $2M | — | $-108M | $-41M | -2001.5% |
| Dec 2024 | — | — | $-114M | $-149M | — |
| Dec 2023 | — | — | $-100M | $-111M | — |
| Dec 2022 | — | — | $-85M | $-12M | — |
| Dec 2021 | — | — | $-81M | $-26M | — |
| Dec 2020 | — | — | $-65M | $-67M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-105M | $1M | $-106M | $-0.26 | — |
| Dec 2024 | $-98M | $2M | $-100M | $-1.26 | — |
| Dec 2023 | $-73M | $2M | $-76M | $-1.07 | — |
| Dec 2022 | $-71M | $1M | $-72M | $-0.12 | — |
| Dec 2021 | $-81M | $0M | $-81M | $-0.66 | — |
| Dec 2020 | $-56M | $0M | $-56M | $-11.54 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $1M (+37.3% on a year earlier), net income $-16M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Sep 28, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Aug 12, 20268-KCurrent reportResults of operations
- Jul 31, 20268-KCurrent reportListing notice
- Jun 11, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- Jun 10, 20268-KCurrent reportOther events
- Jun 9, 20268-KCurrent reportBylaws amended · Shareholder vote
- Jun 5, 20268-KCurrent reportOther events
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 8, 20268-KCurrent reportListing notice
Official filings of Humacyte, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $2 M
- Operating income
- $-108 M
- Net income
- $-41 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $116 M
- Total liabilities
- $113 M
- Total equity
- $3 M
As of December-2025
Top 100 institutional investors in Humacyte, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 10,964,108 | +856,429 (+8.47%) | 3.95% | $6 M | Nov 13, 2026 |
| 2 | ANTIPODES PARTNERS Ltd | 8,258,350 | -1,845,297 (-18.26%) | 2.97% | $4 M | Nov 5, 2026 |
| 3 | BlackRock, Inc. | 4,565,633 | -274,296 (-5.67%) | 1.64% | $2 M | Nov 13, 2026 |
| 4 | Great Point Partners LLC | 3,750,000 | 0 (0.00%) | 1.35% | $2 M | Nov 16, 2026 |
| 5 | UBS Group AG | 3,007,277 | +163,784 (+5.76%) | 1.08% | $2 M | Nov 10, 2026 |
| 6 | Marshall Wace, LLP | 2,996,553 | +2,814,722 (+1547.99%) | 1.08% | $2 M | Nov 13, 2026 |
| 7 | Geode Capital Management, LLC | 2,676,475 | +491,250 (+22.48%) | 0.96% | $1 M | Nov 6, 2026 |
| 8 | Citadel Advisors LLC | 1,733,130 | +289,754 (+20.07%) | 0.62% | $1 M | Nov 16, 2026 |
| 9 | Susquehanna International Group, LLP | 1,670,302 | -28,941 (-1.70%) | 0.60% | $1 M | Nov 16, 2026 |
| 10 | Vanguard Fiduciary Trust Co | 1,599,496 | +418,220 (+35.40%) | 0.58% | $1 M | Nov 13, 2026 |
| 11 | Charles Schwab Investment Management Inc | 1,376,120 | +22,605 (+1.67%) | 0.50% | $1 M | Nov 16, 2026 |
| 12 | Private Advisor Group, LLC | 947,765 | -17,326 (-1.80%) | 0.34% | $0 M | Nov 10, 2026 |
| 13 | LPL Financial LLC | 938,041 | -87,494 (-8.53%) | 0.34% | $0 M | Nov 6, 2026 |
| 14 | Wealth Effects LLC | 919,720 | +225,800 (+32.54%) | 0.33% | $0 M | Oct 23, 2026 |
| 15 | State Street Corp | 900,646 | +58,109 (+6.90%) | 0.32% | $0 M | Nov 12, 2026 |
| 16 | Vanguard Portfolio Management LLC | 767,569 | +199,048 (+35.01%) | 0.28% | $0 M | Nov 13, 2026 |
| 17 | Lion Point Capital, LP | 650,000 | 0 (0.00%) | 0.23% | $0 M | Nov 16, 2026 |
| 18 | Northern Trust Corp | 586,572 | +130,099 (+28.50%) | 0.21% | $0 M | Nov 16, 2026 |
| 19 | Woodline Partners LP | 500,582 | 0 (0.00%) | 0.18% | $0 M | Nov 16, 2026 |
| 20 | Invesco Ltd. | 448,633 | +193,099 (+75.57%) | 0.16% | $0 M | Nov 12, 2026 |
| 21 | Gsa Capital Partners LLP | 334,510 | -671,199 (-66.74%) | 0.12% | $0 M | Nov 16, 2026 |
| 22 | Morgan Stanley | 260,475 | -84,647 (-24.53%) | 0.09% | $0 M | Nov 13, 2026 |
| 23 | LJI Wealth Management, LLC | 252,500 | -17,000 (-6.31%) | 0.09% | $0 M | Oct 28, 2026 |
| 24 | Goldman Sachs Group Inc | 242,915 | -343,609 (-58.58%) | 0.09% | $0 M | Nov 16, 2026 |
| 25 | United Asset Strategies, Inc. | 209,608 | 0 (0.00%) | 0.08% | $0 M | Oct 28, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Hudson Bay Capital Management LP | 195,000 | -180,000 (-48.00%) | 0.07% | $0 M | Nov 13, 2026 |
| 27 | Catalyst Funds Management Pty Ltd | 162,119 | -45,781 (-22.02%) | 0.06% | $0 M | Nov 12, 2026 |
| 28 | Bridgeway Capital Management, LLC | 157,378 | -2,622 (-1.64%) | 0.06% | $0 M | Nov 16, 2026 |
| 29 | Empowered Funds, LLC | 157,378 | New | 0.06% | $0 M | Nov 13, 2026 |
| 30 | Creative Planning | 149,129 | +37,787 (+33.94%) | 0.05% | $0 M | Nov 2, 2026 |
| 31 | Group One Trading LLC | 136,595 | -20,548 (-13.08%) | 0.05% | $0 M | Nov 10, 2026 |
| 32 | Bolton Securities Corporation | 120,000 | 0 (0.00%) | 0.04% | $0 M | Nov 12, 2026 |
| 33 | AQR Capital Management LLC | 114,051 | -2,483,083 (-95.61%) | 0.04% | $0 M | Nov 16, 2026 |
| 34 | LaSalle St. Investment Advisors, LLC | 111,574 | -2,295 (-2.02%) | 0.04% | $0 M | Nov 16, 2026 |
| 35 | Renaissance Technologies LLC | 110,271 | New | 0.04% | $0 M | Nov 12, 2026 |
| 36 | Cetera Investment Advisers | 109,186 | +2,475 (+2.32%) | 0.04% | $0 M | Nov 13, 2026 |
| 37 | Miramontes Capital, LLC | 108,695 | 0 (0.00%) | 0.04% | $0 M | Oct 19, 2026 |
| 38 | Endowment Wealth Management, Inc. | 105,418 | 0 (0.00%) | 0.04% | $0 M | Nov 3, 2026 |
| 39 | Vanguard Global Advisers, LLC | 104,782 | +54,916 (+110.13%) | 0.04% | $0 M | Nov 13, 2026 |
| 40 | Two Sigma Investments, LP | 92,783 | +63,235 (+214.01%) | 0.03% | $0 M | Nov 16, 2026 |
| 41 | Bank Of America Corp /de/ | 88,507 | -490,085 (-84.70%) | 0.03% | $0 M | Nov 16, 2026 |
| 42 | Schonfeld Strategic Advisors LLC | 86,580 | -75,059 (-46.44%) | 0.03% | $0 M | Nov 16, 2026 |
| 43 | Kovack Advisors, Inc. | 82,600 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 44 | Barclays PLC | 76,001 | +36,321 (+91.53%) | 0.03% | $0 M | Nov 6, 2026 |
| 45 | Advisors Capital Management, LLC | 73,657 | New | 0.03% | $0 M | Nov 12, 2026 |
| 46 | Concurrent Investment Advisors, LLC | 71,479 | +2,500 (+3.62%) | 0.03% | $0 M | Oct 16, 2026 |
| 47 | Engineers Gate Manager LP | 61,907 | +48,000 (+345.15%) | 0.02% | $0 M | Nov 16, 2026 |
| 48 | BNP Paribas Financial Markets | 57,634 | -152,151 (-72.53%) | 0.02% | $0 M | Nov 12, 2026 |
| 49 | Integrity Alliance, LLC. | 57,300 | 0 (0.00%) | 0.02% | $0 M | Oct 29, 2026 |
| 50 | Beacon Pointe Advisors, LLC | 56,000 | +20,000 (+55.56%) | 0.02% | $0 M | Nov 16, 2026 |
| 51 | Bank of New York Mellon Corp | 55,844 | 0 (0.00%) | 0.02% | $0 M | Nov 5, 2026 |
| 52 | Osaic Holdings, Inc. | 53,672 | -2,900 (-5.13%) | 0.02% | $0 M | Nov 12, 2026 |
| 53 | China Universal Asset Management Co., Ltd. | 50,687 | +15,353 (+43.45%) | 0.02% | $0 M | Oct 28, 2026 |
| 54 | Clarus Wealth Advisors | 46,545 | +6,574 (+16.45%) | 0.02% | $0 M | Oct 13, 2026 |
| 55 | Letko, Brosseau & Associates Inc | 45,950 | 0 (0.00%) | 0.02% | $0 M | Nov 6, 2026 |
| 56 | Raymond James Financial Inc | 45,670 | -4,132 (-8.30%) | 0.02% | $0 M | Nov 12, 2026 |
| 57 | Merit Financial Group, LLC | 43,475 | -9,337 (-17.68%) | 0.02% | $0 M | Nov 6, 2026 |
| 58 | Chicago Partners Investment Group LLC | 42,489 | +9,143 (+27.42%) | 0.02% | $0 M | Oct 27, 2026 |
| 59 | Financial Advisors Network, Inc. | 41,638 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 60 | Tower Research Capital LLC (TRC) | 33,234 | -6,448 (-16.25%) | 0.01% | $0 M | Nov 16, 2026 |
| 61 | R Squared Ltd | 30,844 | -961 (-3.02%) | 0.01% | $0 M | Nov 6, 2026 |
| 62 | Victory Capital Management Inc | 29,268 | +6,006 (+25.82%) | 0.01% | $0 M | Nov 10, 2026 |
| 63 | Lazari Capital Management, Inc. | 26,444 | +12,000 (+83.08%) | 0.01% | $0 M | Oct 20, 2026 |
| 64 | Trust Co of Kansas | 24,000 | 0 (0.00%) | 0.01% | $0 M | Nov 6, 2026 |
| 65 | MAI Capital Management | 22,418 | -12,242 (-35.32%) | 0.01% | $0 M | Nov 12, 2026 |
| 66 | Columbia Advisory Partners LLC | 21,958 | +2,000 (+10.02%) | 0.01% | $0 M | Oct 15, 2026 |
| 67 | Hamilton Lane Advisors LLC | 21,893 | 0 (0.00%) | 0.01% | $0 M | Oct 21, 2026 |
| 68 | Jpmorgan Chase & Co | 21,534 | +7,944 (+58.45%) | 0.01% | $0 M | Nov 12, 2026 |
| 69 | Waverly Advisors, LLC | 20,495 | -3,177 (-13.42%) | 0.01% | $0 M | Nov 16, 2026 |
| 70 | Great Valley Advisor Group, Inc. | 19,754 | 0 (0.00%) | 0.01% | $0 M | Nov 9, 2026 |
| 71 | Independent Advisor Alliance | 19,500 | +5,000 (+34.48%) | 0.01% | $0 M | Nov 10, 2026 |
| 72 | Jain Global LLC | 18,945 | -95,613 (-83.46%) | 0.01% | $0 M | Nov 16, 2026 |
| 73 | HighTower Advisors, LLC | 18,293 | -4,049 (-18.12%) | 0.01% | $0 M | Nov 10, 2026 |
| 74 | HUB Investment Partners, LLC | 18,250 | New | 0.01% | $0 M | Nov 3, 2026 |
| 75 | PFG Investments, LLC | 17,842 | -50 (-0.28%) | 0.01% | $0 M | Nov 12, 2026 |
| 76 | Mariner, LLC | 17,565 | -157,410 (-89.96%) | 0.01% | $0 M | Nov 12, 2026 |
| 77 | Prosperity Wealth Management, Inc. | 17,500 | — | 0.01% | $0 M | Nov 16, 2026 |
| 78 | Rather & Kittrell, Inc. | 17,350 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 79 | Trilogy Capital Inc. | 17,050 | 0 (0.00%) | 0.01% | $0 M | Oct 20, 2026 |
| 80 | Jones Financial Companies Lllp | 16,870 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 81 | Onyx Bridge Wealth Group LLC | 16,500 | +5,000 (+43.48%) | 0.01% | $0 M | Oct 16, 2026 |
| 82 | Regions Financial Corp | 16,399 | 0 (0.00%) | 0.01% | $0 M | Nov 5, 2026 |
| 83 | Imprint Wealth LLC | 16,363 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 84 | Wealth Watch Advisors, INC | 16,363 | New | 0.01% | $0 M | Nov 16, 2026 |
| 85 | Wealth Enhancement Advisory Services, LLC | 15,702 | -34,328 (-68.61%) | 0.01% | $0 M | Oct 13, 2026 |
| 86 | Uniting Wealth Partners, LLC | 15,609 | 0 (0.00%) | 0.01% | $0 M | Nov 6, 2026 |
| 87 | Accredited Investors Inc. | 15,600 | 0 (0.00%) | 0.01% | $0 M | Nov 3, 2026 |
| 88 | Valeo Financial Advisors, LLC | 15,400 | -4,500 (-22.61%) | 0.01% | $0 M | Oct 8, 2026 |
| 89 | CFS Investment Advisory Services, LLC | 15,000 | 0 (0.00%) | 0.01% | $0 M | Oct 19, 2026 |
| 90 | Nuveen, LLC | 14,660 | +3,290 (+28.94%) | 0.01% | $0 M | Nov 10, 2026 |
| 91 | Mirae Asset Global Investments Co., Ltd. | 14,196 | +4,266 (+42.96%) | 0.01% | $0 M | Oct 29, 2026 |
| 92 | Brookstone Capital Management | 13,984 | +730 (+5.51%) | 0.01% | $0 M | Oct 22, 2026 |
| 93 | Fifth Third Bancorp | 13,180 | +12,486 (+1799.14%) | 0.00% | $0 M | Nov 5, 2026 |
| 94 | Brown Advisory Inc | 13,129 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 95 | Clearview Wealth Management LLC | 13,000 | 0 (0.00%) | 0.00% | $0 M | Oct 16, 2026 |
| 96 | Tudor Investment Corp Et Al | 12,300 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 97 | Vanguard Personalized Indexing Management, LLC | 11,874 | New | 0.00% | $0 M | Nov 16, 2026 |
| 98 | Act Wealth Management, LLC | 11,379 | 0 (0.00%) | 0.00% | $0 M | Oct 9, 2026 |
| 99 | Key Client Fiduciary Advisors, LLC | 10,020 | -1,700 (-14.51%) | 0.00% | $0 M | Oct 19, 2026 |
| 100 | Truist Financial Corp | 10,000 | New | 0.00% | $0 M | Oct 30, 2026 |
Mutual funds holding Humacyte, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 7.72 M | $6 M | 2.8% | <0.01% | +46% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 2.12 M | $2 M | 0.76% | <0.01% | +25% | Jun 30, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 1.44 M | $1 M | 0.52% | 0.01% | +18% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 839,278 | $1 M | 0.30% | <0.01% | +117% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 835,684 | $1 M | 0.30% | <0.01% | +9.1% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 728,581 | $1 M | 0.26% | <0.01% | −1.6% | May 31, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 474,574 | $1 M | 0.17% | <0.01% | −0.9% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 276,545 | $0 M | 0.10% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 233,838 | $0 M | 0.08% | <0.01% | +6.8% | May 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 415,181 | $0 M | 0.15% | <0.01% | +277% | Jul 31, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 243,339 | $0 M | 0.09% | <0.01% | +88% | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 101,891 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 167,033 | $0 M | 0.06% | <0.01% | +2.5% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 96,784 | $0 M | 0.03% | <0.01% | +12% | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 160,000 | $0 M | 0.06% | 0.08% | −24% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 136,276 | $0 M | 0.05% | <0.01% | +136% | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 131,718 | $0 M | 0.05% | <0.01% | +26% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 70,822 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 68,970 | $0 M | 0.02% | <0.01% | +1.4% | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 91,962 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 62,744 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 35,933 | $0 M | 0.01% | <0.01% | +3.0% | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 68,576 | $0 M | 0.02% | <0.01% | +13% | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 55,838 | $0 M | 0.02% | <0.01% | +132% | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 30,744 | $0 M | 0.01% | <0.01% | +19% | Jul 31, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 14,991 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 23,262 | $0 M | <0.01% | <0.01% | +24% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 9,770 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 7,628 | $0 M | <0.01% | <0.01% | +14% | May 31, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 11,911 | $0 M | <0.01% | <0.01% | +21% | Jun 30, 2026 |
| 🇺🇸 Nuveen Nasdaq 100 Dynamic Overwrite FundNuveen Fund Advisors, LLC | 11,370 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 5,965 | $0 M | <0.01% | <0.01% | −38% | May 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 6,034 | $0 M | <0.01% | <0.01% | −37% | May 31, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 3,350 | $0 M | <0.01% | <0.01% | −5.2% | May 31, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 3,124 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 5,134 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 4,026 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 3,863 | $0 M | <0.01% | <0.01% | +18% | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 1,149 | $0 M | <0.01% | <0.01% | +28% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 39 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Humacyte, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Keith Anthony JonesDirector | Buy | +10,000 | $0.560 | $6 K | 50,000 | Form 4 |
| filed | Keith Anthony JonesDirector | Buy | +10,000 | $0.690 | $7 K | 40,000 | Form 4 |
| filed | Keith Anthony JonesDirector | Buy | +30,000 | $0.590 | $18 K | 30,000 | Form 4 |
| filed | Kathleen SebeliusDirector | Buy | +56,818 | $0.880 | $50 K | 148,025 | Form 4 |
| filed | Shamik J. ParikhChief Medical Officer | Sell10b5-1 plan | -45,887 | $0.900 | — | 272,713 | Form 4 |
| filed | Dale A. SanderCFO and Chief Corp. Dev. Off | Sell10b5-1 plan | -45,887 | $0.900 | $41 K | 267,213 | Form 4 |
| filed | Michael T. ConstantinoDirector | Buy | +11,000 | $0.890 | $10 K | 43,950 | Form 4 |
| filed | Shamik J. ParikhChief Medical Officer | Grant or award | +311,100 | — | — | 318,600 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Humacyte, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 42,552 shares at $0.45
- : 183,998 shares at $0.40
- : 700 shares at $0.35
- : 99,686 shares at $0.39
- : 62,702 shares at $0.48
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Humacyte, Inc. scorecard#
Passes 3 of the 15 checks that could be worked out: strongest in financial health (2 of 5), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 28, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median40.2×Price to book 40.2× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median51.9×Price to sales 51.9× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-84.7%Free cash flow is -84.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.26 vs -1.26Diluted EPS -0.26 in fiscal 2025 against -1.26 the year before (report's currency).
- ✓Net income higher than five years earlier-$41 M-$41 M in fiscal 2025 against -$67 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$41 MNet income -$41 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health2 of 5
- ✓Short-term assets cover short-term liabilities3.7×Current ratio 3.69 at the end of fiscal 2025.
- ✗Debt below equity11.4×Debt to equity 11.40 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $15 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-10.62Z-score -10.62 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year33.5%Diluted shares up 33.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Humacyte, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 2.0—100% | 0—— | — | — | — | — | |
| Cost of revenue | 9.7—476% | 0—— | — | — | — | — | |
| Research and development | 69−21.8%3400% | 89+15.7%— | 77+21.0%— | 63+3.1%— | 61+13.4%— | 54—— | |
| General and administrative | 31+20.8%1529% | 26+9.8%— | 23+2.7%— | 23+8.3%— | 21+75.9%— | 12—— | |
| Operating expenses | — | 114+14.3%— | 100+16.1%— | 86+4.5%— | 82+24.8%— | 66—— | |
| Total costs and expenses | 110−3.7%5406% | 114—— | — | — | — | — | |
| Operating income | −108—−5306% | −114—— | −100—— | −85—— | −81—— | −65—— | |
| Interest and finance income | 2.6−37.0%127% | 4.1−24.9%— | 5.5+108%— | 2.6+16331%— | 0.0−94.2%— | 0.3—— | |
| Interest expense and finance costs | 11+21.3%552% | 9.3+40.6%— | 6.6+6.4%— | 6.2+42.6%— | 4.3+97.5%— | 2.2—— | |
| Other non-operating income (expense) | 67—3302% | −34—— | −11−115%— | 73+32.7%— | 55—— | −1.9—— | |
| Income before tax | −41—−2004% | — | — | — | — | — | |
| Income tax | 0—0.0% | 0—— | 0—— | 0—— | 0—— | 0—— | |
| Net income attributable to shareholders | −41—−2004% | −149—— | −111—— | −12—— | −26—— | −67—— | |
| Earnings per share, basic | -0.26—— | -1.26—— | -1.07—— | -0.12—— | -0.66—— | -11.54—— | |
| Earnings per share, diluted | -0.26—— | -1.26—— | -1.07—— | -0.12—— | -0.66—— | -11.54—— | |
| Shares, weighted average (basic) | 158+33.5%— | 118+14.6%— | 103+0.4%— | 103+158%— | 40+593%— | 5.8—— | |
| Shares, weighted average (diluted) | 158+33.5%— | 118+14.6%— | 103+0.4%— | 103+158%— | 40+593%— | 5.8—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 50+12.4%43.4% | 45−44.1%32.6% | 80−46.3%62.7% | 150−31.1%73.3% | 218+445%75.9% | 40r1.1—37.4% | |
| Short-term investments | — | — | 0−100%0.0% | 2.1−73.7%1.0% | 8.0—2.8% | 0—0.0% | |
| Receivables | 0.4—0.4% | 0r0.2—0.0% | 0−100%0.0% | 0.0−82.4%0.0% | 0.2+55.8%0.1% | 0.1—0.1% | |
| Inventory | 14—11.7% | 0—0.0% | — | — | — | — | |
| Other current assets | 3.3+11.8%2.8% | 2.9r2.9+3.3%2.1% | 2.8+23.2%2.2% | 2.3−37.2%1.1% | 3.7—1.3% | — | |
| Current assets | 68+41.7%58.3% | 48−42.5%34.7% | 83−46.0%64.9% | 154−32.8%75.5% | 229+453%80.0% | 41r1.2—38.9% | |
| Property, plant and equipment | 19−19.6%15.9% | 23−13.9%16.7% | 27−10.8%20.9% | 30−14.3%14.7% | 35−14.5%12.2% | 41—38.4% | |
| Right-of-use (leased) assets | 0−100%0.0% | 0.60.0%0.4% | 0.6−14.3%0.5% | 0.7r0.7−3.7%0.3% | 0.7−5.5%0.3% | 0.8—0.7% | |
| Total assets | 116−15.6%100% | 138+7.5%100% | 128−37.2%100% | 204−28.7%100% | 287+169%100% | 107r101—100% | |
| Accounts payable | 5.4+20.4%4.6% | 4.5−30.8%3.3% | 6.5+307%5.1% | 1.6−23.8%0.8% | 2.1−7.9%0.7% | 2.3r0.0—2.1% | |
| Current liabilities | 18−7.9%15.8% | 20+8.2%14.5% | 18−5.8%14.4% | 20+77.2%9.6% | 11−1.6%3.9% | 11r0.2—10.5% | |
| Lease liabilities (non-current) | — | 0.5−16.7%0.4% | 0.60.0%0.5% | 0.6r0.6−12.0%0.3% | 0.7−6.2%0.2% | 0.7—0.7% | |
| Total liabilities | 113−40.6%97.3% | 191+66.2%138% | 115+31.2%89.4% | 87−46.8%42.8% | 164+356%57.4% | 36r2.1—33.8% | |
| Retained earnings | −727—−625% | −686—−498% | −537—−419% | −427—−209% | −415—−145% | −388r−0.2—−364% | |
| Shareholders' equity | 3.1—2.7% | −53−489%−38.2% | 14−88.4%10.6% | 117−4.3%57.2% | 122—42.6% | −350r5.0—−328% | |
| Total equity | — | — | — | — | — | −350—−328% | |
| Total liabilities and equity | 116−15.6%100% | 138+7.5%100% | 128−37.2%100% | 204−28.7%100% | 287+169%100% | 107r101—100% | |
| Shares outstanding | 193+48.4%— | 130+25.4%— | 104+0.4%— | 103+0.2%— | 103+1669%— | 5.8—— | |
| Cash-flow statement | |||||||
| Share-based compensation | 9.8+58.9%479% | 6.1−10.1%— | 6.8+10.4%— | 6.2−39.0%— | 10+116%— | 4.7—— | |
| Cash from operating activities | −105—−5154% | −98—— | −73—— | −71—— | −81—— | −56—— | |
| Capital expenditure | −0.9—−43.4% | −1.6—— | −2.3—— | −1.0—— | −0.2—— | −0.3—— | |
| Cash from investing activities | −0.9—−43.4% | −1.6—— | −0.2−104%— | 4.8—— | −8.2—— | −0.3—— | |
| Debt issued | — | — | — | — | 0−100%— | 3.3—— | |
| Debt repaid | −88—−4318% | 0—— | — | — | — | — | |
| Shares issued | — | — | — | — | 242—— | 0—— | |
| Cash from financing activities | 61−46.2%3017% | 114+2433%— | 4.5—— | −1.4−101%— | 267+12911%— | 2.1—— | |
| Change in cash | −44−407%−2181% | 14—— | −69—— | −68−138%— | 178—— | −54—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 2.4+52.5%100% | 1.0+36.5%100% | 0.4+34.9%100% | 0.5−4.3%100% | 0.5*—100% | 0.8—100% | 0.3—100% | 0.5—100% | 0*—— | 0—— | 0—— | 0—— | — | |
| Cost of revenue | 14+2123%575% | 1.4+450%139% | 1.2+478%303% | 2.0+1286%412% | 9.1*—1945% | 0.3—34.5% | 0.2—70.8% | 0.1—28.4% | 0*—— | 0—— | 0—— | 0—— | — | |
| Research and development | 66−12.0%2768% | 14−18.3%1372% | 18−17.5%4469% | 19+26.2%3932% | 15*−29.3%3127% | 17−24.7%2294% | 22−7.4%7311% | 15−27.5%2982% | 21*+2.4%— | 23—— | 24—— | 21—— | 20*—— | |
| Selling, general and administrative | — | — | — | — | — | 7.6+4.1%1011% | 7.8+35.9%2594% | 8.1+53.1%1574% | — | 7.3—— | 5.7—— | 5.3—— | — | |
| General and administrative | 33+5.2%1360% | 9.0+18.4%877% | 8.0+2.8%1977% | 7.9−2.5%1602% | 7.6*+2.5%1631% | 7.6+4.1%1011% | 7.8+35.9%2594% | 8.1+53.1%1574% | 7.4*+23.8%— | 7.3—— | 5.7—— | 5.3—— | 6.0*—— | |
| Operating expenses | — | — | — | — | — | — | — | — | 28*+7.3%— | 30—— | 29—— | 27—— | 26*—— | |
| Total costs and expenses | 113+5.3%4703% | 25−2.4%2388% | 27−8.7%6749% | 29+24.2%5945% | 31*+11.4%6703% | 25−16.8%3339% | 30+1.8%9976% | 24−10.8%4584% | 28*—— | 30—— | 29—— | 27—— | — | |
| Operating income | −110—−4603% | −24—−2288% | −27—−6649% | −29—−5845% | −31*—−6603% | −24—−3239% | −30—−9876% | −23—−4484% | −28*—— | −30—— | −29—— | −27—— | −26*—— | |
| Interest and finance income | 1.8−37.9%76.0% | 0.6+1.9%58.5% | 0.4−53.4%95.6% | 0.3−50.2%66.7% | 0.5*−41.0%108% | 0.6−35.2%78.4% | 0.8−36.5%276% | 0.7−35.8%128% | 0.9*−25.5%— | 0.9—— | 1.3—— | 1.0—— | 1.1*—— | |
| Interest expense and finance costs | 10−5.7%420% | 2.4−9.3%231% | 2.3−8.8%572% | 2.3−24.3%459% | 3.1*+23.3%662% | 2.6+7.1%347% | 2.5+1.2%846% | 3.0+65.2%580% | 2.5*+45.2%— | 2.4—— | 2.5—— | 1.8—— | 1.7*—— | |
| Other non-operating income (expense) | 16−77.3%648% | 8.0+16.0%776% | −9.8—−2415% | 11−81.8%2286% | 6.0*−15.6%1292% | 6.9—914% | −7.9—−2635% | 62—12055% | 7.1*+564%— | −9.0—— | −27—— | −5.3—— | 1.1*—— | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—— | 0—— | 0—— | 0—— | 0*—— | |
| Net income attributable to shareholders | −95—−3955% | −16—−1511% | −37—−9065% | −18−145%−3559% | −25*—−5311% | −18—−2325% | −38—−12511% | 39—7570% | −21*—— | −39—— | −57—— | −32—— | −25*—— | |
| Earnings per share, basic | — | -0.06—— | -0.16—— | -0.09−132%— | — | -0.11—— | -0.24—— | 0.28—— | — | -0.33—— | -0.48—— | -0.29—— | — | |
| Earnings per share, diluted | — | -0.06—— | -0.16—— | -0.09−132%— | — | -0.11—— | -0.24—— | 0.28—— | — | -0.33—— | -0.48—— | -0.29—— | — | |
| Shares, weighted average (basic) | 278+75.5%— | 278+75.5%— | 234+50.7%— | 198+50.5%— | — | 158+32.6%— | 155+30.4%— | 131+21.5%— | — | 119—— | 119—— | 108—— | — | |
| Shares, weighted average (diluted) | 278+75.5%— | 278+75.5%— | 234+50.7%— | 198+50.2%— | — | 158+32.6%— | 155+30.4%— | 132+21.7%— | — | 119—— | 119—— | 108—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 65—51.4% | 65+231%51.4% | 80+110%57.9% | 49−22.8%43.9% | 50+12.4%43.4% | 19−5.3%21.3% | 38−59.4%27.4% | 63−45.6%38.7% | 45−44.1%32.6% | 21—17.9% | 94—67.7% | 116—71.5% | 80—62.7% | |
| Short-term investments | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Receivables | 0.8—0.6% | 0.8−24.8%0.6% | 0.3−16.2%0.2% | 0.4−11.1%0.4% | 0.4—0.4% | 1.1—1.2% | 0.4—0.3% | 0.5—0.3% | 0r0.2—0.0% | — | — | — | 0—0.0% | |
| Inventory | 5.6—4.5% | 5.6−69.5%4.5% | 7.0−36.9%5.1% | 9.9+23.7%9.0% | 14—11.7% | 18—20.1% | 11—8.0% | 8.0—4.9% | 0—0.0% | — | — | — | — | |
| Other current assets | 2.6—2.1% | 2.6+10.5%2.1% | 5.6+149%4.0% | 4.7+100%4.3% | 3.3+11.8%2.8% | 2.4−2.8%2.6% | 2.2−12.2%1.6% | 2.4−2.9%1.4% | 2.9r2.9+3.3%2.1% | 2.4—2.1% | 2.5—1.8% | 2.4—1.5% | 2.8—2.2% | |
| Current assets | 83—65.8% | 83+99.9%65.8% | 93+79.4%67.2% | 64−13.7%57.5% | 68+41.7%58.3% | 41+79.7%45.2% | 52−46.2%37.3% | 74−37.5%45.3% | 48−42.5%34.7% | 23—20.0% | 96—69.5% | 118—73.0% | 83—64.9% | |
| Property, plant and equipment | 15—11.9% | 15−25.0%11.9% | 16−23.7%11.7% | 17−22.5%15.7% | 19−19.6%15.9% | 20−18.1%21.7% | 21−14.6%15.3% | 22−12.5%13.8% | 23−13.9%16.7% | 24—21.1% | 25—17.9% | 26—15.9% | 27—20.9% | |
| Right-of-use (leased) assets | — | — | — | — | 0−100%0.0% | 0—0.0% | — | — | 0.60.0%0.4% | — | — | — | 0.6—0.5% | |
| Total assets | 126—100% | 126+37.2%100% | 138−0.5%100% | 111−32.0%100% | 116−15.6%100% | 92−20.3%100% | 139+0.4%100% | 163+0.7%100% | 138+7.5%100% | 115—100% | 138—100% | 161—100% | 128—100% | |
| Accounts payable | 2.8—2.2% | 2.8−70.5%2.2% | 4.2−37.3%3.0% | 5.1−8.8%4.6% | 5.4+20.4%4.6% | 9.6+38.7%10.5% | 6.6+10.4%4.8% | 5.6+61.4%3.4% | 4.5−30.8%3.3% | 6.9—6.0% | 6.0—4.3% | 3.5—2.1% | 6.5—5.1% | |
| Current liabilities | 25—19.7% | 25−3.2%19.7% | 15−29.1%10.8% | 16−19.2%14.6% | 18−7.9%15.8% | 26+22.2%28.0% | 21+18.7%15.2% | 20+42.2%12.3% | 20+8.2%14.5% | 21—18.2% | 18—12.8% | 14—8.7% | 18—14.4% | |
| Lease liabilities (non-current) | — | — | — | — | — | — | — | — | 0.5−16.7%0.4% | — | — | — | 0.6—0.5% | |
| Total liabilities | 108—85.6% | 108+11.7%85.6% | 107−20.7%77.4% | 99−21.8%89.5% | 113−40.6%97.3% | 96−46.1%105% | 135−19.1%97.1% | 127−6.5%77.8% | 191+66.2%138% | 178—156% | 167—120% | 135—83.8% | 115—89.4% | |
| Retained earnings | −797—−635% | −797—−635% | −781—−566% | −744—−673% | −727—−625% | −702—−767% | −685—−493% | −647—−398% | −686—−498% | −665—−580% | −626—−453% | −569—−353% | −537—−419% | |
| Shareholders' equity | 18—14.4% | 18—14.4% | 31+671%22.6% | 12−67.7%10.5% | 3.1—2.7% | −4.8—−5.2% | 4.1—2.9% | 36+37.8%22.2% | −53−489%−38.2% | −64—−55.5% | −28—−20.5% | 26—16.2% | 14—10.6% | |
| Total liabilities and equity | 126—100% | 126+37.2%100% | 138−0.5%100% | 111−32.0%100% | 116−15.6%100% | 92−20.3%100% | 139+0.4%100% | 163+0.7%100% | 138+7.5%100% | 115—100% | 138—100% | 161—100% | 128—100% | |
| Shares outstanding | 278—— | 278+74.9%— | 278+77.7%— | 222+43.1%— | 193+48.4%— | 159+32.5%— | 156+31.0%— | 155+30.3%— | 130+25.4%— | 120—— | 119—— | 119—— | 104—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 11+16.0%442% | 2.3−6.7%228% | 2.6+7.1%642% | 3.2+27.5%640% | 2.5*+45.8%529% | 2.5+61.7%333% | 2.4+69.4%809% | 2.5+71.0%481% | 1.7*+20.5%— | 1.6—— | 1.4—— | 1.5—— | 1.4*—— | |
| Cash from operating activities | −88—−3684% | −15*—−1457% | −22*—−5434% | −25—−5072% | −26*—−5594% | −24*—−3175% | −26*—−8775% | −29—−5532% | −27*—— | −23*—— | −21*—— | −27—— | −19*—— | |
| Capital expenditure | −0.3—−13.3% | 0*—0.0% | −0.1*—−25.6% | −0.2—−35.4% | −0.0*—−8.4% | −0.0*—−6.5% | −0.6*—−189% | −0.2—−44.1% | −0.1*—— | −0.9*—— | −0.2*—— | −0.4—— | −0.2*—— | |
| Cash from investing activities | −0.3—−13.3% | 0*—0.0% | −0.1*—−25.6% | −0.2—−35.4% | −0.0*—−8.4% | −0.0*—−6.5% | −0.6*—−189% | −0.2—−44.1% | −0.1*—— | −0.9*—— | −0.2*—— | −0.4—— | −0.2*—— | |
| Shares issued | — | — | — | — | — | — | — | — | — | — | 0*—— | 43—— | — | |
| Cash from financing activities | 134+142%5577% | −0.4*—−39.5% | 54*+2371%13184% | 23−50.1%4711% | 57*+12.1%12242% | −45*−5352%−5922% | 2.2*—720% | 47−25.6%9040% | 51*—— | 0.8*—— | −0.5*—— | 63—— | −0.3*—— | |
| Change in cash | 45—1880% | −15*—−1496% | 31*—7725% | −2.0−111%−396% | 31*+27.3%6640% | −69*—−9103% | −25*—−8244% | 18−48.9%3464% | 24*—— | −23*—— | −22*—— | 35—— | −20*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Humacyte, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product(total)$1 M68%—
- Contract Revenue$1 M32%—
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Humacyte, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. Niklason | $5.2 M | −$725 K | $2.1 M | $34 |
| 2024Laura E. Niklason | $905 K | $2.9 M | $678 K | $178 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Humacyte, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Directors and officers 1 · Material agreement 9 · Agreement ended 2 · New debt 2 · Unregistered share sale 1 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 7
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Material agreement | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Agreement ended | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Agreement ended | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Lobbying by Humacyte, Inc.#
$120 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues, medicare/medicaid and defense.
- Health Issues5 reports
- Medicare/Medicaid2 reports
- Defense2 reports
Lobbying firms hired in 2025
Capitol Hill Consulting Group $100 K · G2G Consulting $20 K · DLA Piper LLP (US)
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $150 K | — | 3 |
| 2025 | $120 K | — | 6 |
| 2024 | $60 K | — | 6 |
| 2023 | $10 K | — | 2 |
| 2021 | $110 K | — | 3 |
| 2020 | $200 K | — | 4 |
| 2019 | $200 K | — | 4 |
| 2018 | $200 K | — | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Humacyte, Inc.” and “Humacyte”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
How Humacyte, Inc. compares in Biotechnology
- Market cap$125 M · higher than 39% of 726
- Revenue$2 M · higher than 30% of 647
- Price / sales51.9× · lower than 17% of 339
- Price / book40.2× · lower than 4% of 534
- FCF yield-84.7% · higher than 12% of 449
- 🇺🇸 Nkarta, Inc.$125 M
- 🇹🇼 Mycenax Biotech Inc.$124 M
- 🇺🇸 Anavex Life Sciences Corp.$123 M
- 🇺🇸 Foghorn Therapeutics Inc.$123 M
- 🇹🇼 UnicoCell Biomed Co., Ltd.$129 M
- 🇺🇸 Immunic, Inc.$121 M
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Humacyte, Inc.🇺🇸 | $125 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Humacyte, Inc.? Verify and update this profile — free
Show Humacyte, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.